RE: RE: RE: WOW! Brad is talking wild!I agree with your point rjc2827. Licensing agreements can take many shapes and Oncolytics is in the driver seat with the intellectual property rights to Reolysin and close to $60 million in cash. They need a partner to provide the muscle to get large studies done or take the slow route by going on alone. Common sense favours partnering. Retaining control of manufacturing also makes sense. It provides Oncolytics with a greater revenue base to continue to expand the development of Reolysin to other cancers and beyond.
The purpose of my post was to counter Pericles1’s dismissive comments. He trivialized Brad’s comments that manufacturing was his “stay awake” issue. Brad pointed out that many examples of companies failing to get a product registered after a successful pivotal due to FDA’s concerns regarding manufacturing. Brad’s confidence in Reolysin passing trial end points is understandable. He has access to individual patient and seen summaries of trial results. He covered the correlation between low grade fever results and a positive result. With around 450 patients treated, he has a body of work to be confident. It is only the Brad whiners like Pericles who spread doubt by worrying about the pivotal trial.